anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients in the intervention arm will receive the Empowering Patients in Chronic Care group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
Chronic pelvic pain caused by the sequelae of inflammatory pelvic disease is a common clinical condition of pelvic pain in women. At present, the main challenges in its treatment are the limited effectiveness of pain relief and the frequent recurrence of symptoms, which significantly impact patients' quality of life and impose a considerable psychological burden on them. It is a clinically challenging disease. After summarizing years of treatment experience, the author's team discovered that acupoint catgut embedding demonstrated notable clinical efficacy in managing chronic pelvic pain stemming from pelvic inflammatory disease sequelae. Compared to existing Western medicine treatment methods, acupoint catgut embedding offers advantages such as a good analgesic effect, lower recurrence rate, economic benefits, and a relatively straightforward procedure. This article provides a comprehensive guide on embedding absorbable catgut into patients' acupoints for the treatment of chronic pelvic pain in females resulting from the sequelae of pelvic inflammatory disease.
In adult patients and pediatric patients 10 years of age or older with epilepsy previously receiving divalproex sodium delayed-release tablets, divalproex sodium extended-release tablets should be administered once-daily using a dose 8% to 20% higher than the total daily dose of divalproex sodium delayed-release tablets (Table 1). For patients whose divalproex sodium delayed-release tablets total daily dose cannot be directly converted to divalproex sodium extended-release tablets, consideration may be given at the clinician’s discretion to increase the patient’s divalproex sodium delayed-release tablets total daily dose to the next higher dosage before converting to the appropriate total daily dose of divalproex sodium extended-release tablets.

Table 1. Dose Conversion

There is insufficient data to allow a conversion factor recommendation for patients with divalproex sodium delayed-release tablets doses above 3,125 mg/day. Plasma valproate C min concentrations for divalproex sodium extended-release tablets on average are equivalent to divalproex sodium delayed-release tablets, but may vary across patients after conversion. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 mcg/mL to 100 mcg/mL) [see Clinical Pharmacology (12.2)] .
BACKGROUNDS: A recent randomized control trial (JCOG1202; ASCOT trial) demonstrated the efficacy of adjuvant S-1 chemotherapy (ASC) for biliary tract cancer (BTC) after surgical resection; however, the significance of the completion of ASC in the real-world setting remains unknown.
METHODS: Data of consecutive patients who underwent surgical resection for biliary tract cancer (BTC) from 2011 to 2021 were retrospectively reviewed. Of these, patients who underwent ASC were enrolled in this study. Patients were divided into two groups according to whether ASC was completed: the completion group and the non-completion group. Clinicopathological features and survival outcomes were assessed.
RESULTS: Of the 223 patients with BTC who underwent surgical resection, 75 patients who underwent ASC were included for analysis. Among them, 48 (64.0 %) completed the intended ASC course, while 27 cases (36.0 %) discontinued the treatment. The most common reason for the discontinuation was adverse event (n = 16, 59.3 %), followed by disease recurrence (n = 9, 33.3 %). Patients in the completion group showed significantly better overall survival (OS) (p < 0.001) and recurrence-free survival (RFS) (p < 0.001) compared to the non-completion group. Further, after excluding the patients in the non-completion group who discontinued ASC due to disease recurrence, the significance of ASC completion was retained for both OS and RFS.
CONCLUSION: The completion of ASC was associated with improved prognosis in patients with BTC after surgical resection. The achievement of ASC should be the goal after surgical resection, while further study may be warranted regarding the resistance of ASC.
Methods, systems, and computer-storage media are provided for a extracting real-time data to generate utilization models and reports for improving the utilization of a surgical block within a healthcare system. Sets of real-time data are extracted from a first source, a second source, and a third source. The sets of data are processed, validated, and transformed into a first set of utilization data. The first set of utilization data is analyzed and a utilization model is generated based on such analysis. Additionally, a report, which includes the utilization model, is generated for display to a user via a user interface. The use of the report and utilization model allow for implementing changes to scheduling and workflow that result in increasing surgical block utilization rates.
A composition suitable for use as a shampoo comprises a concentrated aqueous solution of a synthetic detergent, preferably an anionic or non-ionic detergent, which also contains in solution a free acid. Immediately before use, a powdered carbonate or bicarbonate is added to the solution, and the gas given off aerates the mixture and causes it to foam.  A number of suitable anionic and non-ionic detergents are specified.  The acid may be any acid without harmful effect on the hair and scalp but is preferably citric, tartaric or lactic acids.  The carbonate or bicarbonate may be that of an alkali or alkaline-earth metal. Specification 415,559 is referred to.ALSO:A shampoo comprises a concentrated aqueous solution of a synthetic detergent, preferably an anionic or non-ionic detergent, which also contains in solution a free acid.  Immediately before use, a powdered carbonate or bicarbonate is added to the solution, and the gas given off aerates the mixture and causes it to foam. A number of suitable anionic and non-ionic detergents are specified.  The acid may be any acid without harmful effect on the hair and scalp but is preferably citric, tartaric or lactic acid. The carbonate or bicarbonate may be that of an alkali or alkaline-earth metal.  Specification 415,559 [Group III] is referred to.
Extubation criteria: partial pressure carbon dioxide (pCO2) ≥ 60mmHg with an upper limit ≤ 75mmHg; pH ≥ 7.20; oxygen saturation (SpO2) ≥ 88% with fraction of inspired oxygen (FiO2) ≤ 0.50; mean airway pressure (MAP) \< 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude \< 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 \> 75mmHg; pH \< 7.20; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (\> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
OBJECTIVES: Frailty is a dynamic health state that changes over time. Our hypothesis was that there are identifiable subgroups of the older population that have specific patterns of deterioration. The objective of this study was to evaluate the application of joint latent class model in identifying trajectories of frailty progression over time and their group-specific risk of death in older people.
STUDY DESIGN AND SETTING: The primary care records of UK patients, aged over 65 as of January 1, 2010, included in the Clinical Practice Research Datalink: GOLD and AURUM databases, were analyzed and linked to mortality data. The electronic frailty index (eFI) scores were calculated at baseline and annually in subsequent years (2010-2013). Joint latent class model was used to divide the population into clusters with different trajectories and associated mortality hazard ratios. The model was built in GOLD and validated in AURUM.
RESULTS: Five trajectory clusters were identified and characterized based on baseline and speed of progression: low-slow, low-moderate, low-rapid, high-slow, and high-rapid. The high-rapid cluster had the highest average starting eFI score; 7.9, while the low-rapid cluster had the steepest rate of eFI progression; 1.7. Taking the low-slow cluster as reference, low-rapid and high-rapid had the highest hazard ratios: 3.73 (95% CI 3.71, 3.76) and 3.63 (3.57-3.69), respectively. Good validation was found in the AURUM population.
CONCLUSION: Our research found that there are vulnerable subgroups of the older population who are currently frail or have rapid frailty progression. Such groups may be targeted for greater healthcare monitoring.
PROBLEM TO BE SOLVED: To obtain a 2-in-1 type cleaning composition capable of effectively cleaning the hair to impart excellent combing easiness and softness, enabling the application of considerable amount of treating agent to the hair and skin and having high frothing property by including at least one kind of water-soluble silicone agent, at least one kind of a cationic condition controlling agent and at least one kind of a detergent. SOLUTION: This cleaning composition contains (A) at least one kind of water-soluble silicone agent (e.g. silicone quaternium 13) in an amount of preferably 0.001-20 wt.% (B) at least one kind of cationic agent (e.g. acrylamide propyl trimmonium chloride/acrylamide copolymer) in an amount of preferably 0.01-10 wt.% and (C) at least one kind of detergent (e.g. ammonium lauryl sulfate) in an amount of preferably 0.01-30 wt.%. The composition may further contain an active amount of agent to be applied to a desired part of the skin, hair and/or nail.
Trials with a new, first -in-class drug will be done to ascertain safety, tolerability, and to explore efficacy in the treatment of rheumatoid arthritis, including its effects on biomarkers. Approximately 240 adult patients with rheumatoid arthritis despite the use of methotrexate therapy will be recruited for the study. They will be randomly assigned to one of 4 treatment arms; each patient has an equal chance of receiving the placebo, or 100 mg, 200 mg, 300 mg dose of RWJ-445380. Patients will take the medication daily for up to 12 weeks. Patients will receive study medication in a blinded fashion, i.e. the patient, the doctor and the study sponsor will not know what group the patient is in until all patients complete the study. The investigator and the sponsor will monitor the study for the occurrence of possible side effects. In addition to a screening visit, patients will have visits every week for the first 2 weeks then every 2 weeks until 12 weeks of treatment. After 12 weeks, there will be a followup visit 4 weeks after the last dose of study drug is taken. Medical history, physical examination, blood pressure, heart rate, temperature, and ECGs are checked periodically. Joints will be assessed to explore whether the drug might affect tender and swollen joints. Blood samples will be taken for standard safety laboratory tests as well as special tests of the drug blood level, biomarkers to see whether the drug might be affecting the biological pathway of antigen presentation, and other markers for rheumatoid arthritis. Samples will also be taken to see whether certain types of immune cells are affected by taking the drug. Immunization with tetanus vaccine will be done to see if taking the drug might affect immune responses to this agent Patients will receive RWJ-445380, 100, 200, 300 mg, or placebo. Patients will receive oral capsules daily for up to 12 weeks.
A drug composition for use in a method of treatment of an ocular disease or condition, wherein the drug composition is for delivery to the suprachoroidal or supraciliary space by a device, wherein the composition comprises a semisolid material, wherein the semisolid material comprises a drug; flows under injection pressure; remains localised at the site of injection during and immediately after injection; and the semi-solid material undergoes dissolution after injection to migrate in the suprachoroidal space is provided. The semisolid material preferably comprises an excipient that undergoes dissolution, biodegradation or bioerosion. The excipient may be polyethylene oxide. The drug may be a steroid, a non-steroidal anti-inflammatory agent, a VEGF inhibitor, an anti-TNF alpha agent, an mTOR inhibitor, cell therapy, nucleic acid based therapeutic and/or a neuroprotectant. The drug may be dexamethasone. A device for delivery of a drug composition to the suprachoroidal space or supraciliary space is also described.
Anemia is sometimes seen in patients receiving NSAIDs, including indomethacin extended-release capsules. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including indomethacin extended-release capsules, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia.   
  
NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving indomethacin extended-release capsules who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.
The impact of MPA Injectable Suspension, USP (150 mg) use for up to 240 weeks (4.6 years) was evaluated in an open-label non-randomized clinical study in 389 adolescent females (12 to 18 years of age). Use of MPA Injectable Suspension, USP was associated with a significant decline from baseline in BMD. 

Partway through the trial, drug administration was stopped (at 120 weeks). The mean number of injections per MPA Injectable Suspension, USP user was 9.3. Table 5 summarizes the study findings. The decline in BMD at total hip and femoral neck was greater with longer duration of use. The mean decrease in BMD at 240 weeks was more pronounced at total hip (-6.4%) and femoral neck (-5.4%) compared to lumbar spine (-2.1%).

Adolescents in the untreated cohort had an increase in BMD during the period of growth following menarche. However, the two cohorts were not matched at baseline for age, gynecologic age, race, BMD and other factors that influence the rate of acquisition of BMD.

BMD Recovery Post-Treatment in Adolescents 

Longer duration of treatment and smoking were associated with less recovery of BMD following the last injection of MPA Injectable Suspension, USP. Table 6 shows the extent of recovery of BMD up to 60 months post-treatment for adolescents who received MPA Injectable Suspension, USP for two years or less compared to more than two years. Post-treatment follow-up showed that, in women treated for more than two years, only lumbar spine BMD recovered to baseline levels after treatment was discontinued. Adolescents treated with MPA Injectable Suspension, USP for more than two years did not recover to their baseline BMD level at femoral neck and total hip even up to 60 months post-treatment. Adolescents in the untreated cohort gained BMD throughout the trial period (data not shown) [see Warnings and Precautions (5.1)].
PURPOSE:To obtain the subject forming agent composed of a specific polyalkylene oxide derivative and capable of introducing a (poly)oxyalkylene chain into a small capsulated material, e.g. liposome and easily and efficiently immobilizing various kinds of functional materials at the tip of the chain. CONSTITUTION:This forming agent is composed of a reactive polyalkyleneoxide derivative of the formula [R<1> and R<2> are each a 3-30C aliphatic acid acyl residue; AO is a 2-4C oxyalkylene; (n) is an average addition molar number of the AO of 1-1000; X and Y are each a divalent organic group; (p) is 0 or 1; M<1> and M<2> are each H or an alkali metal atom]. Further, the compound of the formula is obtained e.g. by reacting phosphatidylethanolamine and a (poly) alkylene oxide derivative having carboxylic acid halides at both ends at the charging molar ratio of 1:1 to 1:1000 with each other in the presence of a tertiary amine, e.g. triethylamine and subsequently hydrolyzing an active ester group remaining in the reaction mixture.
Norepinephrine in Sodium Chloride Injection (norepinephrine bitartrate) is supplied as a clear, colorless sterile solution in a 250 mL non-PVC infusion bag with single function connector system consisting of a port and cap, packaged individually in an aluminum foil pouch with an oxygen scavenger. Supplied as:

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Protect from light. Keep in sealed overwrap until ready to use. Discard after 24 hours of opening overwrap.
If hybrid closed-loop systems (HCLS) ("artificial pancreas") for automated insulin administration have demonstrated their great interest in patients living with moderately unbalanced type 1 diabetes (T1D) (HbA1c \< 8 .6% on average), no study has looked at their safety, acceptability and efficacy in patients living with highly and chronically unbalanced T1D (HbA1c \> 11%). These patients, often young, present more or less advanced microangiopathic complications (retinopathy, nephropathy, neuropathy, etc.) or are highly exposed to the appearance of these complications, the prevention of which, whether primary or secondary, involves obtaining a good glycemic balance over time. These patients "escape" the possibilities of current insulin therapy, whether by multiple insulin injections or by insulin pump, more or less coupled to a continuous glucose monitoring system. Automated insulin delivery systems could be a solution to achieve less catastrophic glycemic control in some of these patients. The investigators are proposing a pilot study aimed at evaluating acceptability, safety and effectiveness of a HCLS currently available in France (the SMARTGUARD™ MINIMED™ 780G or the Control-IQ) in patients followed in the diabetology department of the Centre Hospitalier Sud-Francilien (CHSF), living with highly unbalanced T1D (HbA1c \> 11%) in the context of usual follow-up.
Remimazolam is an ultra-short benzodiazepine that acts on the benzodiazepine site of γ-aminobutyric acid (GABA) receptors in the brain and induces sedation. Although GABA receptors are found localized in the spinal dorsal horn, no previous studies have reported the analgesic effects or investigated the cellular mechanisms of remimazolam on the spinal dorsal horn. Behavioral measures, immunohistochemistry, and in vitro whole-cell patch-clamp recordings of dorsal horn neurons were used to assess synaptic transmission. Intrathecal injection of remimazolam induced behavioral analgesia in inflammatory pain-induced mechanical allodynia (six rats/dose; p < 0.05). Immunohistochemical staining revealed that remimazolam suppressed spinal phosphorylated extracellular signal-regulated kinase activation (five rats/group, p < 0.05). In vitro whole-cell patch-clamp analysis demonstrated that remimazolam increased the frequency of GABAergic miniature inhibitory post-synaptic currents, prolonged the decay time (six rats; p < 0.05), and enhanced GABA currents induced by exogenous GABA (seven rats; p < 0.01). However, remimazolam did not affect miniature excitatory post-synaptic currents or amplitude of monosynaptic excitatory post-synaptic currents evoked by Aδ- and C-fiber stimulation (seven rats; p > 0.05). This study suggests that remimazolam induces analgesia by enhancing GABAergic inhibitory transmission in the spinal dorsal horn, suggesting its potential utility as a spinal analgesic for inflammatory pain.
Engaging in regular physical activity that requires a moderate to vigorous effort is related to good health and a reduced risk of a multitude of diseases. Currently physical activity and health promotion research is limited by self- report data that is confounded by participants' ability to accurately remember and record their physical activity. A potentially new method of accurately assessing moderate-intensity physical activity is called context sensitive- ecological momentary assessment (CS-EMA). Mobile computing devices (personal computing devices, PDAs) that automatically identify when a specific type of physical activity (e.g., moderate-intensity physical activity) is being performed has the potential to provide valuable objective data for naturalistic, experimental, and clinical intervention research purposes, and has the potential for educational, recreational, and clinical applications. The goal of this exploratory study is to assess the accuracy of two methods of collecting data on moderate-intensity physical activity. The study will compare the use of a paper diary to collect self-reported data on moderate-intensity physical activities performed throughout the day to self-reported data collected using ecological momentary assessment methods which are facilitated by a PDA that cues the participant to record when specific intensity levels of physical activity are achieved. This study will also develop algorithms that will automatically identify specific types of physical activities being performed. The data collected from the heart rate monitor, motion sensor, and information requested directly from the participant via the PDA interface will be used to train pattern recognition systems to classify the intensity and type of physical activity being performed by the participant. This study will contribute to research on context- awareness and human activity recognition.
PURPOSE:To provide a remedy for hypertension, containing KOJI (rice malt) as an active component. CONSTITUTION:KOJI is produced by the aerobic cultivation of a mold (e.g. belonging to Monascus genus or Aspergillus genus, such as Monascus anka, Monascus pilosus, etc., at 20-40 deg.C for 2-14 days, and is used as an active component to obtain the remedy for hypertension. The component may be combined with various vehicles and carriers, etc., and administered in the form of powder, granule, tablet, capsule, paste, solution, etc. It can be used also as a food obtained by adding KOJI or its processed product to various foods, or as a fermented food taking advantage of the saccharifying power of the KOJI. It is administered as a food or peroral drug at a dose of 1-200g/day to achieve moderate improvement of the hypertension.
In the first part, 100 patients with multiple sclerosis are included. A vision-specific health-related quality of life scale and neuro-ophthalmological tests are administered. The duration of intervention is about 3 hours by patient and one year to finish this part.

In the second part, we include about 40 of 100 MS patients who present an oscillopsia due to pendular nystagmus and a group of 20 control subjects. The patients and subject will perform a motion detection task and the vision-specific health-related quality of life, the intervention lasting 1 hour. Then the patients will be randomized in one group treated by rehabilitation (one 30 mn session per week during 3 months) and the other one without treatment. A motion detection task and the vision-specific health-related quality of life scale will be performed at the end of the treatment for both groups.